Vpliv seva Lactobacillus reuteri DSM 17938 na črevesno mikrobioto novorojenčkov, zdravljenih z antibiotiki

Šetina, Urška (author), Rogelj, Irena (mentor)

Lactobacillus reuteri DSM 17938 (L. reuteri DSM 17938) je dobro proučen probiotičen sev. Študije so pokazale, da lahko zmanjša obolevnost pri dojenčkih z zelo nizko porodno maso, je koristen pri modulaciji črevesne mikrobiote, odpravljanju okužb in blažitvi driske, povezane z antibiotiki. Namen naše raziskave, ki je bila del randomizirane, s placebom kontrolirane študije o vplivu seva L. reuteri DSM 17938 na novorojenčke, zdravljene z antibiotiki (ClinicalTrials.gov: NCT02865564), je bil proučiti razlike v črevesni mikrobioti otrok, tretiranih z antibiotiki in otrok, ki so vzporedno z antibiotično terapijo prejemali probiotični sev L. reuteri DSM 17938. Zbranih in analiziranih je bilo skupno 161 vzorcev blata od 87 dojenčkov, ki so bili naključno razdeljenih v testno (TS = 43 otrok) in placebo (P = 44 otrok) skupino. Vzorci so se zbirali 6 tednov od začetka terapije ter pri 1 letu starosti otrok. Izvedli smo kvantitativni PCR (qPCR) za bakterije rodu Lactobacillus, družine Enterobacteriaceae, rodu Bifidobacterium, sev L. reuteri DSM 17938 in celotno bakterijsko populacijo. Poleg vpliva seva na črevesno mikrobioto otrok smo preverjali tudi vpliv spola, načina hranjenja in načina poroda. Dojenje je vplivalo na oblikovanje črevesne mikrobiote, saj so imeli otroci, ki so bili pri 2 mesecih dohranjevani, v blatu odvzetem 6 tednov od začetka terapije, večje deleže bakterij družine Enterobacteriaceae, seva L. reuteri in bakterij rodu Lactobacillus. Način poroda in spol otrok nista vplivala na samo sestavo mikrobiote blata otrok 6 tednov od začetka terapije in pri 1 letu starosti otrok. V blatu otrok, tretiranih z L. reuteri DSM 17938, smo detektirali prisotnost probiotičnega seva v 28 % vzorcev blata, odvzetih po 6-ih tednih od začetka terapije. Kljub temu, da smo potrdili prisotnost seva L. reuteri DSM 17938 in da je ta zmožen kolonizirati črevesje, prisotnost probiotičnega seva ni vplivala na delež preiskovanih predstavnikov mikrobiote. Uživanje seva ni vplivalo na velikost mikrobne populacije in deleže mikrobnih populacij bifidobakterij, enterobakterij in laktobacilov v vzorcih blata otrok 6 tednov od začetka terapije in pri 1 letu starosti otrok.

• Language: Slovenian
• Keywords: probiotiki, Lactobacillus reuteri DSM 17938, novorojenčki, črevesna mikrobiota, antibiotiki, dojenje
• Work type: Master's thesis/paper
• Typology: 2.09 - Master's Thesis
• Organization: BF - Biotechnical Faculty
• Place of publishing: Ljubljana
• Publisher: [U. Šetina]
• Year: 2022
• PID: 20.500.12556/RUL-142667
• UDC: 579.2:612.33:615.33
• COBISS.SI-ID: 130661123
• Publication date in RUL: 19.11.2022

Secondary language

• Language: English
• Title: Effect of Lactobacillus reuteri DSM 17938 on intestinal microbiota of infants treated with antibiotics

Abstract

Lactobacillus reuteri DSM 17938 (L. reuteri DSM 17938) is a well-studied probiotic strain. Studies have shown that it can reduce morbidity in infants with very low birth weight, it is used in modulating gut microbiota, reducing infections, and treating antibiotic-associated diarrhoea. The aim of our study, which was part of randomized, placebo-controlled trial on the effect of L. reuteri DSM 17938 on antibiotic-treated infants (ClinicalTrials.gov: NCT02865564), was to examine differences in intestinal microbiota of infants, treated with antibiotics, and infants who received the probiotic strain L. reuteri DSM 17938 concurrently with antibiotic therapy. A total of 161 fecal samples from 87 infants, who were randomized into intervention group (TS = 43 infants) and placebo group (P = 44 infants), were collected 6 weeks after the start of therapy and at 1 year of age and then analysed. Quantitative PCR analysis was performed for Lactobacillus genus, Enterobacteriaceae family, Bifidobacterium genus, L. reuteri DSM 17938 strain and entire bacterial population. We also examined the influence of gender, feeding method and mode of delivery. Breastfeeding influenced the formation of the intestinal microbiota, as infants who were supplemented at 2 months of age had higher proportions of Enterobacteriaceae, L. reuteri and Lactobacillus in their fecal samples, taken 6 weeks after the start of therapy. The mode of delivery and gender didn't influence the composition of the fecal microbiota in samples taken 6 weeks after the start of therapy and at 1 year of age. The presence of L. reuteri 17938 strain was detected in 28 % of fecal samples of infants in intervention group at 6 weeks after the start of therapy. Despite the fact that we confirmed the presence of L. reuteri DSM 17938 strain and that it is able to colonize the intestines, it did not affect the proportion of the investigated representatives of the microbiota. Consumption of the strain did not affect the size of microbial populations of bifidobacteria, enterobacteria and lactobacilli in the stool samples taken 6 weeks after the start of therapy and at 1 year of age.

• Keywords: probiotics, Lactobacillus reuteri DSM 17938, infants, intestinal microbiota, antibiotics, breastfeeding